Bevacizumab Gamma

Summary

Bevacizumab Gamma (CHEMBL5314727) is an approved antibody; indicated across 1 condition including wet macular degeneration.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• Indications: 1 condition

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5314727
Name	Bevacizumab Gamma
Type	Antibody
Max phase	4

Also known as: Bevacizumab gamma, Lytenava, BEVACIZUMAB GAMMA

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
wet macular degeneration	4	MONDO:0005417	EFO:0004683

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).